US medical malpractice data can provide early warning signals for UK healthcare liability claims. Trends in areas such as aesthetics and GLP-1 medications consistently emerge in the US first, offering UK insurers and indemnifiers a window to act before trends mature. 

The two systems are, after all, structurally different - no civil juries, different costs rules, the NHS and a compensation framework that bears little surface resemblance to the mass tort environment that characterises US litigation. It is perhaps understandable that the transatlantic comparison has not been a routine part of how UK insurers and indemnifiers think about emerging risk.

But a closer look at the data suggests that may be a missed opportunity. In reviewing claims trends, litigation developments and regulatory responses on both sides of the Atlantic, we have observed recurring patterns across a range of clinical areas including sepsis, obstetrics, aesthetics, cauda equina syndrome, and missed cancer diagnosis.

Trends can be seen in the same clinical risk areas, the same failures and the same escalation in claim severity, with the US running roughly a decade ahead. Although lead time varies by subject matter, there is evidence that the gap is narrowing, with some trends now moving from the US to the UK far more quickly than has historically been the case. By understanding these patterns, insurers, indemnifiers, and the healthcare providers can identify emerging risks before they become mature sources of liability within the UK.

How the US healthcare liability trends signal emerging UK risks

The relevant question is no longer whether liability trends will emerge in both jurisdictions, but how quickly lessons from one market maybe become visible in the other. While the US has historically been roughly a decade ahead in many areas of healthcare liability, there is growing evidence that the warning period is shrinking. As litigation trends, regulatory responses and patient expectations evolve more rapidly, the opportunity to identify and respond to emerging risks before they mature may become increasingly limited.

The US often reaches the point at which a clinical issue becomes a systemic liability exposure first. In doing so, it provides an early view of the plaintiff strategies, severity pressures, regulatory responses and defence challenges that may later emerge in the UK. It shows which cases attract funding, which fact patterns generate large awards, which failures resonate with courts, regulators and the public, and which clinical issues evolve into portfolio-level exposures.

By the time those lessons become fully visible in the UK, the opportunity for early intervention may already have passed. Used properly, the US experience becomes less a comparison exercise and more a form of horizon scanning. The objective is not to import American litigation concerns into the UK, but to identify emerging risks early enough to influence governance, reserving, claims handling and defence strategy before the exposure reaches maturity.

One example of this dynamic can already be seen in the UK aesthetics market, where rapid commercial growth appears to be outpacing the development of mature governance and claims experience

Aesthetics: A pattern already in motion

The US aesthetics liability peaked during the 2000s and into the 2010s, driven by rapid growth in elective cosmetic procedures, commercialisation of treatments, and a loosely regulated environment. 

In the UK, the aesthetics market is currently akin to the Wild West with limited regulation and plans for regulatory reforms to be introduced – expected in early 2026. These would restrict who is able to carry out aesthetics treatments with the most invasive treatments restricted only to trained and licenced healthcare professionals. 

When considering the claims landscape it seems likely that the UK is on the same curve as the US so the key is to act early before claims have a chance to peak. 

The US experience suggests that when the claims wave arrives, it is the providers operating at scale, under commercial pressure, and ahead of settled clinical governance frameworks who face the greatest exposure. Steps in the UK to address this should be taken now to avoid a future spike in claims. 

The rise of weight loss medications in the UK

The newest craze is in GLP-1s which have transformed obesity treatment. A UCL study found that 1.6 million people used GLP-1 medications in the UK in 2025 alone. For many patients, these drugs are safe, effective, and genuinely life-changing. The liability risk for insurers and indemnifiers is not the drugs themselves but how they are prescribed, monitored, marketed, and documented.

The sequence that follows such rapid clinical uptake is familiar. A new treatment generates initial enthusiasm, rapid market growth, and increased prescribing volume. Thereafter complications emerge, regulators intervene and litigation follows. That sequence is already well advanced in the United States and the UK can look to the US for how we may see claims arise. 

In many respects, weight-loss injections represent exactly the type of emerging risk where transatlantic comparison is most valuable. The UK is not witnessing a new clinical phenomenon, but rather a rapidly expanding treatment model operating at scale. The US experience provides an opportunity to observe how prescribing practices, consent processes, monitoring obligations and claimant behaviour evolve before those exposures become established sources of loss, reserving uncertainty and litigation cost within the UK healthcare sector. 

How GLP-1 litigation is developing in the US

US multidistrict litigation has consolidated over 3,000 lawsuits alleging that GLP-1 medications caused serious harm including permanent gastroparesis, sudden blindness, and intestinal blockages, alongside other serious injuries. Critically, those claims have been brought against manufacturers rather than clinicians. In the US, product liability routes are well established and well funded. 

On the other hand in the UK, clinical negligence claims are generally easier to pursue than product liability claims. When the litigation wave arrives in the UK, the proposed defendant is far more likely to be the prescriber than the manufacturer so UK clinicians should be prepared to respond to claims.  

Risk of group litigation 

The characteristics that create mass litigation risk are already present in the weight-loss injection market: high-volume prescribing, significant commercial pressure, online delivery models, vulnerable patient populations, intense media attention, and rapidly evolving clinical evidence. 

This combination is precisely the environment in which claims proliferate and group litigation forms. The US experience of over 3,000 consolidated lawsuits should serve as a direct signal that UK insurers and indemnifiers need to anticipate not just individual claims, but potential group actions.

What UK insurers and indemnifiers should do now about weight-loss medication risk

For insurers and indemnifiers, the US experience points to clear, actionable steps:

• Keep abreast of regulatory developments from the MHRA/NICE and evolving guidance.
• Follow how litigation in other jurisdictions continues to develop.
• Scrutinise consent documentation, risk disclosures, patient information materials, and digital records of patient interactions among insureds operating in this space. Do they go beyond the formulaic and genuinely evidence an informed discussion about realistic outcomes and risks?
• Apply particular caution to online prescribing models and new drugs or methods of delivery where clinical governance frameworks may not yet have kept pace with commercial scale.
• Be prepared to anticipate novel claims and group litigation not simply individual cases.

The UK has not traditionally looked west for early warnings. Perhaps it should start. The emerging risk from weight-loss injections is not that the injections do not work - it is that rapid commercialisation may outpace clinical governance. When access becomes too easy, screening becomes superficial, consent becomes formulaic, and monitoring becomes inadequate, liability follows. The US has already written that chapter. The UK does not have to repeat it.

These article builds on themes discussed in detail at a recent Medical Malpractice seminar held in London in July 2026, where we heard from speakers Nicola Campbell-Clause of Hailsham Chambers, Karen Salmon of Gallagher Bassett, and Jonathan Fuggle and Gerard Hanratty of Browne Jacobson. 

The authors continue to monitor developments in the UK and US healthcare liability trends and welcome discussion on the issues raised. Get in touch with Karen Salmon, UK Professional Liability Director at Gallagher Bassett and Lucy Bowdery, Senior Associate at Browne Jacobson.